Life-threatening abdominal wall hematoma in a chronic renal failure patient after a single dose of enoxaparin

American Surgeon

Volumn 71, Issue 2, 2005, Pages 132-134

  Weinsheimer, Robert L ^a   Libby, Edward ^a   Howdieshell, Thomas R ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; ANTICOAGULANT AGENT;

ABDOMINAL MASS; ABDOMINAL PAIN; ABDOMINAL WALL; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; FEMALE; HEMATOMA; HEMODYNAMICS; HUMAN; LABORATORY TEST; LUNG VENTILATION PERFUSION RATIO; PREOPERATIVE EVALUATION; THORAX PAIN; TREATMENT OUTCOME; ABDOMINAL INJURY; BLEEDING; EPIGASTRIC ARTERY; FOLLOW UP; INJURY; PATHOLOGY; TRAFFIC ACCIDENT;

ABDOMINAL INJURIES; ABDOMINAL WALL; ACCIDENTS, TRAFFIC; ADULT; ANTICOAGULANTS; ENOXAPARIN; EPIGASTRIC ARTERIES; FEMALE; FOLLOW-UP STUDIES; HEMATOMA; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 22844447645     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hirsh J, Warkentin TE, Raschker L. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(5 Suppl):489-500.
2. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188-203.
3. Harrison L, McGinnis J, Crowther M. Assessment of outpatient treatment of deep-venous thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-10.
4. Gould MK, Dembitzer AD, Sanders GD. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis, a meta-analysis of randomized controlled trials. Ann Intern Med 1999;130:800-25.
5. Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998;56:259-66.
6. Landefeld CS, McGuire E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1990;89: 569-77.
7. Nieuwenhuis HK, Albada J, Banga JD. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78:2337-46.
8. Bergquist D, Born GU, Arfors KE. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis. Br J Surg 1997;84:1099-103.
9. Noble S, Spencer CM. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995;49:388-400.
10. Boneu B, deMoerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001;27:519-22.
11. Farooq V, Hegarty J, Chandrasekar T. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004;43:531-7.
12. Sanderink GM, Guimart CG, Ozoux ML. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-31.
13. DuToit DF, Maritz J, Loxton AJ. Rectus sheath hematoma, a complication of anticoagulant therapy. S Afr Med J 1983;63: 902-4.